Roche Receives FDA Approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay

On November 14, 2022, the U.S Food and Drug Administration (FDA) approved the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry companion diagnostic test to aid in identifying epithelial ovarian cancer patients who are eligible for targeted treatment with mirvetuximab soravtansine-gynx.

For more information, read the Roche announcement.

Posted 11/16/2022